



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 219054 Neostigmine Juno neostigmine methylsulfate 2.5 mg/1 ml solution for injection ampoule

ARTG entry for Medicine Registered
Sponsor Horizon Hospital Healthcare Pty Ltd
Postal Address PO Box 175, CARNEGIE, VIC, 3163
 Australia
ARTG Start Date 27/01/2015
Product category Medicine
Status Active
Approval area Drug Safety Evaluation Branch

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. Neostigmine Juno neostigmine methylsulfate 2.5 mg/1 ml solution for injection ampoule

Product Type	Single Medicine Product	Effective date	23/05/2016
---------------------	-------------------------	-----------------------	------------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Reversal of the effects of non-depolarising neuromuscular blocking agents (e.g. tubocurarine, pancuronium etc). Prophylaxis and treatment of post-operative intestinal atony and urinary retention. Treatment of myasthenia gravis during acute exacerbations, when the condition is severe or in neonates.

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Ampoule	Glass Type I Clear	36 Months	Store below 25 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
50 ampoules	(S4) Prescription Only Medicine
10 ampoules	(S4) Prescription Only Medicine

Components

1. Neostigmine Juno neostigmine methylsulfate 2.5 mg/1 ml solution for injection ampoule

Dosage Form Injection, solution

Route of Administration Intravenous
 Intramuscular
 Subcutaneous

Visual Identification Clear, colourless solution

Active Ingredients

neostigmine methylsulfate 2.5 mg

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary